Why Indian pharmaceutical companies run the risk of driving up U.S. consumer drug prices when scaling too quickly: the diseconomics of scale. Why the U.S. looks to India as a global supply chain hub for medications India’s pharmaceutical industry saves U.S. consumers billions, but scaling too fast is a mistake. Premature scaling through mergers and
The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.